Another reversible PI under clinical assessment is delanzomib, an orally bioavailable structural homolog of bortezomib with a peptide-like backbone and a boronate warhead.565 It is assessed in several phase I/II clinical trials for MM, lymphoma, and solid tumors.566,567 Compared with BTZ, delanzomib showed slightly reduced efficacy against MM and some solid tumor cells, but had higher selectivity to cancer cells over normal cells, which means better drug safety. The gene discussed is CASC3; the disease is Miyoshi myopathy.